Theratechnologies Inc.

03:41 PM EST - Theratechnologies Inc. : Announced that the Food and Drug Administration in the United States has approved the new single-vial formulation of EGRIFTA® (tesamorelin for injection). EGRIFTA® is a growth hormone-releasing factor analog and is the only FDA-approved treatment for excess abdominal visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. Theratechnologies Inc.
shares T.TH are trading up $0.26 at $8.85.